Global Finance News
30 Apr 2026, 17:47
Alnylam Pharmaceuticals reported strong first-quarter 2026 results, driven by rapid growth in its transthyretin (TTR) franchise.
Global net product revenue reached $1.04 billion, up 121% year-over-year, with TTR-related revenues contributing $910 million, a 153% increase. The performance reflects strong adoption of the company’s therapies in ATTR-related conditions.
Alnylam reiterated its full-year 2026 guidance, expecting total product revenues of $4.9–$5.3 billion, including $4.4–$4.7 billion from its TTR portfolio.
On the clinical side, new data presented at ACC.26 supported the use of Vutrisiran as a first-line treatment for ATTR-CM. The company also announced collaborations with Viz*ai and the American Heart Association to improve early diagnosis and patient care.
With multiple clinical readouts expected in the second half of 2026, Alnylam emphasized continued pipeline momentum and long-term growth potential.
Source: Company press release
Global net product revenue reached $1.04 billion, up 121% year-over-year, with TTR-related revenues contributing $910 million, a 153% increase. The performance reflects strong adoption of the company’s therapies in ATTR-related conditions.
Alnylam reiterated its full-year 2026 guidance, expecting total product revenues of $4.9–$5.3 billion, including $4.4–$4.7 billion from its TTR portfolio.
On the clinical side, new data presented at ACC.26 supported the use of Vutrisiran as a first-line treatment for ATTR-CM. The company also announced collaborations with Viz*ai and the American Heart Association to improve early diagnosis and patient care.
With multiple clinical readouts expected in the second half of 2026, Alnylam emphasized continued pipeline momentum and long-term growth potential.
Source: Company press release
